Crossmark

Evolocumab como tratamiento de la dislipemia secundaria a lorlatinib

Crossref DOI link: https://doi.org/10.1016/j.arteri.2022.12.003

Published Print: 2023-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Pérez Alonso, Laura

Cervera Calero, Raquel

Campos Fernández de Sevilla, María Ángeles

Moreno Palanco, Miguel Ángel

Gómez Cerezo, Jorge Francisco
License Information

Text and Data Mining valid from 2023-03-01
More Information

This article is maintained by: Elsevier

Article Title: Evolocumab como tratamiento de la dislipemia secundaria a lorlatinib

Journal Title: Clínica e Investigación en Arteriosclerosis

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.arteri.2022.12.003

Content Type: article

Copyright: © 2023 Sociedad Española de Arteriosclerosis. Published by Elsevier España, S.L.U. All rights reserved.